FogPharma’s lead program is a peptide that blocks a difficult-to-drug pathway inside of cells. The new financing will go toward an ongoing Phase 1/2 study in advanced solid tumors and support development of pipeline programs for other elusive cancer targets.
Orbis Medicines is developing macrocyclic peptides that address a wider range of targets and can be taken as oral pills. Novo Holdings and Forbion are backing the startup, which is based on research from the scientific co-founder of peptide drug developer Bicycle Therapeutics.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Stealth is moving towards Phase 3 trials in primary mitochondrial myopathy – a common denominator in many mitochondrial diseases – with an emphasis on improving patients' quality of life.